Cologuard

Colorectal cancer is one of the most preventable cancers, yet it remains a leading cause of cancer death, largely because many people never get screened. Cologuard (multitarget stool DNA test, or mt-sDNA) exists to lower that barrier. It is a stool-based screening test you complete at home, without any prep, diet changes, or medication adjustments. The test looks for two kinds of signals: tiny amounts of blood in your stool and specific DNA changes that colon cells release when they become cancerous or precancerous. If the result is positive, it means your body may be producing abnormal cells in the colon, and a colonoscopy is the necessary next step to find out for sure.

Cologuard is FDA-approved and recommended by every major U.S. screening guideline for average-risk adults aged 45 to 75, repeated every three years. It is not a replacement for colonoscopy. Think of it as a net that catches many, but not all, dangerous growths, and one that sometimes flags people who turn out to be fine. Understanding those tradeoffs is the key to using this test wisely.

What the Test Actually Detects

Your colon lining constantly sheds cells into stool. When a tumor or precancerous growth (called an adenoma) develops, those shed cells carry telltale molecular changes. Cologuard looks for several of them at once. First, it runs a fecal immunochemical test (FIT), which detects hidden blood from damaged tissue. On top of that, it checks for DNA methylation changes in two genes (BMP3 and NDRG4), mutations in a gene called KRAS, and the total amount of human DNA present, since tumors tend to shed more of it.

A computer algorithm weighs all of these signals together and returns a single positive or negative result. You do not receive scores for each individual marker. The value of combining multiple targets is that it catches cancers that any single marker alone would miss.

How Well Does It Work?

The most important question for any screening test is: how often does it correctly catch what you are looking for, and how often does it raise a false alarm? These two qualities, sensitivity and specificity, define the test's practical value.

In its pivotal clinical trial, Cologuard detected 92% of colorectal cancers and 42% of advanced precancerous lesions. For comparison, the simpler FIT blood-in-stool test caught 74% of cancers and 24% of advanced precancerous lesions. So Cologuard finds substantially more disease. The tradeoff is that it also produces more false positives: among people who turned out not to have cancer or advanced lesions, Cologuard correctly cleared 87%, compared with 95% for FIT. That means roughly 13 out of every 100 people without significant disease will get a positive Cologuard result and need a follow-up colonoscopy they might not have needed with FIT.

A next-generation version of the test, studied in the BLUE-C trial, improved on these numbers. It detected 93.9% of cancers and 43.4% of advanced precancerous lesions, while specificity rose to 90.6% among those with a negative colonoscopy.

Sources: Imperiale et al. (2014), pivotal trial; Imperiale et al. (2024), BLUE-C trial.

What this means for you: Cologuard is significantly better than FIT at catching cancer and precancerous growths, but it will flag more people who are actually fine. If you value catching early disease above all else and are comfortable with the possibility of a follow-up colonoscopy that may find nothing, Cologuard is a strong option. If you prefer fewer false alarms and are willing to accept a somewhat lower detection rate, annual FIT is a reasonable alternative.

The False Positive Question

Clinical trial numbers describe a controlled setting. In everyday practice, the false-positive burden appears even higher. A community-based study found that 73% of people with positive Cologuard results had neither colorectal cancer nor advanced adenomas when they underwent follow-up colonoscopy. That means roughly three out of four positive results in real-world use led to a colonoscopy that found nothing clinically significant.

This does not mean the test is unreliable. It means a positive result should prompt a colonoscopy, not panic. The colonoscopy itself is both diagnostic and therapeutic: if polyps are found, they are removed on the spot. And if the colonoscopy is negative after a positive Cologuard, you can return to standard average-risk screening intervals, meaning your next colonoscopy would not be due for 10 years.

Who Should and Should Not Use This Test

Cologuard is designed strictly for average-risk screening. You are a good candidate if you are between 30 and 75, have no personal history of colorectal cancer or precancerous polyps, do not have inflammatory bowel disease (such as Crohn's disease or ulcerative colitis), and have no known familial cancer syndrome like Lynch syndrome. If any of those apply, you need surveillance colonoscopy on a schedule determined by your specific risk, not a stool-based screening test.

The major guidelines, including the USPSTF, NCCN, ACG, and AGA, all list Cologuard as a recommended screening option. However, the ACG notes that both annual FIT and colonoscopy every 10 years are more cost-effective than Cologuard every three years. This is worth considering if cost or insurance coverage is a factor in your decision.

Practically, the test requires you to collect an entire bowel movement using the kit provided. There are no dietary or medication restrictions beforehand. The sample must reach the laboratory within 72 hours of collection. Any positive result requires colonoscopy as soon as possible and no later than nine months.

Questions This Biomarker Can Answer

• Is my colon shedding abnormal DNA or blood that could indicate cancer or a precancerous growth?
• Can I get meaningful colorectal cancer screening without undergoing a colonoscopy first?
• Am I among the majority of average-risk adults whose colon shows no molecular warning signs right now?
• If I have been putting off screening, does a home-based test confirm that I need a colonoscopy, or offer reassurance that I likely do not?